Initial indications of CDK18 potential involvement in tumor progression emerged from studies showing that silencing CDK18 inhibited the growth of cutaneous T-cell lymphoma cells, suggesting that CDK18 may play a role in promoting their growth [123]. The gene discussed is CDK18; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.